170 related articles for article (PubMed ID: 8049503)
1. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units.
Shimada Y; Rothenberg M; Hilsenbeck SG; Burris HA; Degen D; Von Hoff DD
Anticancer Drugs; 1994 Apr; 5(2):202-6. PubMed ID: 8049503
[TBL] [Abstract][Full Text] [Related]
2. 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.
Saijo N; Nishio K; Kubota N; Kanzawa F; Shinkai T; Karato A; Sasaki Y; Eguchi K; Tamura T; Ohe Y
Cancer Chemother Pharmacol; 1994; 34 Suppl():S112-7. PubMed ID: 8070019
[TBL] [Abstract][Full Text] [Related]
3. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro.
Burris HA; Hanauske AR; Johnson RK; Marshall MH; Kuhn JG; Hilsenbeck SG; Von Hoff DD
J Natl Cancer Inst; 1992 Dec; 84(23):1816-20. PubMed ID: 1331485
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors.
Kurtzberg LS; Battle T; Rouleau C; Bagley RG; Agata N; Yao M; Schmid S; Roth S; Crawford J; Krumbholz R; Ewesuedo R; Yu XJ; Wang F; Lavoie EJ; Teicher BA
Mol Cancer Ther; 2008 Oct; 7(10):3212-22. PubMed ID: 18852125
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.
Hare CB; Elion GB; Houghton PJ; Houghton JA; Keir S; Marcelli SL; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 1997; 39(3):187-91. PubMed ID: 8996518
[TBL] [Abstract][Full Text] [Related]
6. Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells.
Kim JS; Amorino GP; Pyo H; Cao Q; Choy H
Radiother Oncol; 2002 Jan; 62(1):61-7. PubMed ID: 11830313
[TBL] [Abstract][Full Text] [Related]
7. In vitro antitumor effect of topoisomerase-I inhibitor, CPT-11, on freshly isolated human gastric and colorectal cancer.
Tsunoda T; Tanimura H; Hotta T; Tani M; Iwahashi M; Tanaka H; Matsuda K; Yamaue H
Anticancer Res; 1999; 19(6B):5451-5. PubMed ID: 10697576
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
Houghton PJ; Cheshire PJ; Hallman JC; Bissery MC; Mathieu-Boué A; Houghton JA
Cancer Res; 1993 Jun; 53(12):2823-9. PubMed ID: 8504425
[TBL] [Abstract][Full Text] [Related]
9. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38.
Dodds HM; Haaz MC; Riou JF; Robert J; Rivory LP
J Pharmacol Exp Ther; 1998 Jul; 286(1):578-83. PubMed ID: 9655905
[TBL] [Abstract][Full Text] [Related]
10. Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
van Ark-Otte J; Kedde MA; van der Vijgh WJ; Dingemans AM; Jansen WJ; Pinedo HM; Boven E; Giaccone G
Br J Cancer; 1998 Jun; 77(12):2171-6. PubMed ID: 9649129
[TBL] [Abstract][Full Text] [Related]
11. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Bissery MC; Vrignaud P; Lavelle F; Chabot GG
Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
Shinkai T; Arioka H; Kunikane H; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Oshita F; Nishio M; Karato A
Cancer Res; 1994 May; 54(10):2636-42. PubMed ID: 8168091
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors.
Kunimoto T; Nitta K; Tanaka T; Uehara N; Baba H; Takeuchi M; Yokokura T; Sawada S; Miyasaka T; Mutai M
Cancer Res; 1987 Nov; 47(22):5944-7. PubMed ID: 3664496
[TBL] [Abstract][Full Text] [Related]
15. Future directions for clinical research with CPT-11 (irinotecan).
von Hoff D
Eur J Cancer; 1996; 32A Suppl 3():S9-12. PubMed ID: 8943659
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of irinotecan.
Chabot GG
Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.
Ikuno N; Soda H; Watanabe M; Oka M
J Natl Cancer Inst; 1995 Dec; 87(24):1876-83. PubMed ID: 7494232
[TBL] [Abstract][Full Text] [Related]
19. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo.
Mitsui I; Kumazawa E; Hirota Y; Aonuma M; Sugimori M; Ohsuki S; Uoto K; Ejima A; Terasawa H; Sato K
Jpn J Cancer Res; 1995 Aug; 86(8):776-82. PubMed ID: 7559102
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
